Octagon Therapeutics, a preclinical-stage biopharmaceutical company developing targeted medicines for autoimmune disease, has announced the initiation of a research collaboration with Novo Nordisk focused on inflammatory disease. This multi-year relationship will apply Octagon’s functional target discovery approach and novel chemistry strategy in disease areas in which Novo Nordisk has specific expertise.

Latham & Watkins LLP represents Octagon Therapeutics in the deal with a healthcare and life sciences team led by Bay Area partner Jekkie Kim.